{"url_path":"/sec/ltrn/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023758-index.html","accession_number":"0001493152-26-023758","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023758-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":140,"has_tables":true,"body_markdown":"** **\n\n**Item\n2.02 Results of Operations and Financial Condition.**\n\n \n\nOn\nMay 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first\nquarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated\nherein by reference.\n\n \n\nThe\ninformation in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the\nSecurities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,\nnor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless\nof any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing."}